RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%

New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation.

The subgroup response was lower than the overall trial population, which showed a higher overall response rate.

After the data were released, RevMed’s shares dropped more than 6 percent, reflecting investor concern.

Analysts said the results may open a window for alternative treatments targeting this mutation group.